WO1997032213A1 - Blood testing kit - Google Patents

Blood testing kit Download PDF

Info

Publication number
WO1997032213A1
WO1997032213A1 PCT/US1997/002889 US9702889W WO9732213A1 WO 1997032213 A1 WO1997032213 A1 WO 1997032213A1 US 9702889 W US9702889 W US 9702889W WO 9732213 A1 WO9732213 A1 WO 9732213A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
membrane
blood
limited portion
absorbent pad
Prior art date
Application number
PCT/US1997/002889
Other languages
French (fr)
Inventor
Howard Greenspan
John Colanduoni
Original Assignee
Majesco Biologicals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Majesco Biologicals, Inc. filed Critical Majesco Biologicals, Inc.
Priority to AU21912/97A priority Critical patent/AU2191297A/en
Publication of WO1997032213A1 publication Critical patent/WO1997032213A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing

Definitions

  • This invention relates generally to appara t us for testing blood including tests for blood type or viral infections, such as HIV. More specifically, this invention relates to the use of membranes in blood testing apparatuses.
  • Blood testing is normally performed in a laboratory setting requiring several steps for each type of test to be performed. While the present invention is directed toward two basic type of blood tests, blood type testing and testing for viral infections, other applications will be apparent to those skilled in the art.
  • Blood typing is performed by detecting the type of antigen that is contained within a person's blood. Specifically, a person with A type blood has the A antigen in their blood cells; people with B type blood have the B antigen in their blood cells; people with AB type blood have both the A antigen and the B antigen in their blood cells; and people with 0 type blood have neither the A nor the B antigen.
  • Another process utilizes size exclusion chromatography.
  • a mixture of blood and antibody is placed in a test tube on top of a layer of gel.
  • the tube is then placed in a centrifuge. If the sample contains red cells with the specific antigen on their surface, the cells and antibody will clump together and will not be able to be centrifuged through the gel.
  • the antigen or reactant could be disposed on an underside or an opposing side of a membrane. Blood then could be forced to proceed through the membrane before reacting with the antigen or other reactant. The remaining components of the blood could be thereafter absorbed or washed away leaving the blood cell-reactant aggregate disposed against the underside of the membrane. Because membranes are clear, the result could be an easy-to-read indicator such as a line or a dot. Further, separate antigens or reactants could be placed at discrete locations on the membrane to provide multiple indication in one test kit.
  • both A type and B type as well as RH positive antibodies could be placed on discrete areas of the membrane so that one test apparatus could provide positive indications for A, B, AB, O, RH positive and RH negative blood.
  • Such a system would not require the use of a centrifuge or excessive handling by a technician.
  • the invention is an improved apparatus for testing blood, such as testing blood type and testing for viral infections.
  • One apparatus made in accordance with the present invention includes a backing sheet for accommodating a membrane on one surface section of the backing sheet and an absorbent pad on a second surface section of the backing sheet.
  • the membrane and absorbent pad are in a juxtaposed relationship with one another.
  • antibodies corresponding to A, B and RH positive blood cells are arranged in discrete areas of the membrane.
  • One preferred method is to place a horizontal "stripe" of antibody corresponding to each blood type in a parallel relationship.
  • the backing sheet, absorbent pad and membrane are then cut into strips.
  • the purpose of the absorbent pad is to absorb liquid as it flows through the membrane. When the blood cells react with an antibody or other reagent, the aggregation is too large to pass through the membrane and a red stripe appears where the antibody or reagent was placed on the membrane.
  • a second and related embodiment features a membrane mounted onto the top of an absorbent pad.
  • the absorbent pad includes a hole or aperture disposed in the middle of the pad.
  • the membrane/ pad combination are then accommodated in a housing which includes an opening or access hole disposed above the portion of the membrane covering the hole or opening in the absorbent pad.
  • the appropriate antibodies or reagents are previously placed in discrete areas of the membrane portion which is disposed over the hole in the pad. Blood is then applied directly to the top of the membrane and subsequently washed away with a buffer solution. Blood cells which react with the antibodies or reagents form an aggregation or bright red area after the remaining components of the blood are washed away with the buffer solution.
  • a membrane having approximately a 20 micron pore size is preferable for use with both blood testing apparatuses described above.
  • Red blood cells are approximately seven to eight microns in diameter. Thus, unreacted red blood cells will pass through the 20 micron membrane. However, once the red blood cells react with an antibody or other suitable reagent to produce an aggregate, the aggregate cannot pass through the 20 micron pore size. As the remaining components of the blood are washed away w ch a buffer solution, the aggregate combination is left behind :o provide a bright red indicator on the under surface of the membrane. Because the membranes are transparent, a clear visual indication is provided.
  • a membrane with a smaller pore size, such as 3-6 microns is provided so that the blood and reagents will bind to the surface of the membrane.
  • Still another object of the present invention is to provide an improved apparatus for testing viral infections in human blood. Another object of the present invention is to provide an improved method for testing blood.
  • Figure 1 is a schematic diagram illustrating a positive reaction between an antibody and a red blood cell with the specific antigen and a negative reaction between an antibody and a red cell without the specific antigen;
  • Figure 2 is an illustration of the prior art method of using size exclusion chromatography in testing blood
  • Figure 3 is a top plan view of a plastic backing sheet used in one blood testing apparatus made in accordance with the present invention
  • Figure 4 is a top plan view of the plastic backing sheet shown in Figure 3 with a membrane applied to a lower surface section thereof,-
  • Figure 5 is an illustration of the backing sheet and membrane shown in Figure 4 further with an absorbent pad attached to the backing sheet in a juxtaposed relationship with respect to the membrane;
  • Figure 6 is an illustration of the embodiment shown in Figure 5, cut into strips and illustrating the reactions for A- , A+, B- , B+, AB-, AB+, O- and 0+ blood types;
  • Figure 7 is a side view illustrating the attachment of a membrane to an absorbent pad for a second embodiment made in accordance with the present invention.
  • Figure 8 is a top plan view of the absorbent pad first shown in Figure 7;
  • Figure 9 is a side sectional view illustrating the membrane and absorbent pad shown in Figure 7 contained within a housing.
  • Figure 10 is an illustration of eight blood testing apparatus shown in Figure 9 indicating A- , A+, B-, B+ AB-, AB+, O- and 0+ blood types.
  • FIG. 1 an antibody 11, a red blood cell 12 and a red blood cell 13 are shown at the left.
  • the red blood cell 12 includes an antigen which will react positively with the antibody 11 which will result in an aggregation, shown generally at 14.
  • the aggregation 14 is a positive reaction or a positive indication that the red blood cell 12 is of the blood type specific to the antibody 11.
  • the antibody 11 will not react with the red blood cell 13 because the red blood cell 13 lacks the specific antigen.
  • the combination of the antibody 11 and the red blood cell 13 is a negative reaction or lack of clumping, indicated generally at 15.
  • the aggregation or agglutination shown at 14 is useful in size exclusion chromatography as shown m Figure 2.
  • a size exclusion chromatography method is illustrated in Figure 2.
  • a test tube 16 is filled with a gel 17.
  • a mix type of red blood cells and a specific antibody are placed on top of the gel 17 at the area indicated generally at 18.
  • the test tube 16 is then placed in a centrifuge (not shown) . If no reaction takes place between the antibody and the red blood cells, the red blood cells shown at 20 will centrifuge downward toward the lower end of the test tube below the gel, indicated generally at 19.
  • the test tube shown m the middle of Figure 2 indicates a negative reaction, because the red blood cells 20 were able to pass through the gel 17 during the centrifuge process.
  • red blood cells shown in the test tube 16 at the far right of Figure 2 reacted with the antibody and formed an aggregation 21 which was not able to pass through the gel 17 during the centrifuge process.
  • the red blood cells in combination with the antibodies are shown at 21, disposed on top of the gel 17.
  • the aggregation was unable to pass through the gel and therefore the area disposed at the bottom 19 of the test tube 16 remains clear.
  • the size exclusion chromatography process shown m Figure 2 is inconvenient for several reasons. Specifically, only one antibody or reagent may be used at a time. Thus, several tests are required to determine blood type which requires the use of several test tubes. Further, a centrifuge is required.
  • Figure 3 is an illustration of a backing sheet 22 which, as shown in Figure 4, accommodates a membrane 23.
  • the dotted lines 24, 25 which pass through the membrane 23 are intended to indicate the placement of antibodies on either the top side or underside of the membrane 23.
  • Figure 5 illustrates the placement of an absorbent pad 26 on top of the backing sheet 22 and m a juxtaposed relationship with respect to the membrane 23. As fluid passes through the membrane 23, it is absorbed into the pad 26.
  • the apparatus 27 shown in Figure 5 can then be cut into strips 28a tnrough 28h as shown in Figure 6.
  • the membrane 23 has been coated with three specific antibodies -- the specific antibody for A type blood, the specific antibody for B type blood and the specific antibody for RH+ blood. As illustrated to the left of the strip
  • the A type, B type and RH+ antibodies are coated on the membrane in spaced apart parallel stripes.
  • the use of the three different antibodies enables the test strips 28 to indicate eight different results.
  • the test strip 28a gives a positive indication for A- blood.
  • the test strip 28b is a positive indication for A+ blood.
  • the test strip 28c gives a positive indication for B- blood; the test strip 28d gives a positive indication for B+ blood.
  • the test strips 28e and 28f gives positive results for AB- and AB+ blood respectively.
  • test strips 28g, 28h give positive results for 0- and
  • test strips 28a through 28h as shown m Figure 6 can be used as follows: the blood samples are collected in a standard method with any type of anticoagulant to stop clotting. Approximately five microliters of blood is then added to a 12mm by 75mm test tube along with approximately 95 microliters of buffer containing 1% BSA, 50mM sodium phosphate ph 7.4, with 0.1 percent sodium azide . The strip 28 is then added to the tube with the membrane 23 on the bottom and the solution is allowed to migrate up the strip 28 to the absorbent pad 26. The results can then be observed within one to four minutes.
  • a second embodiment of the present invention is illustrated in Figure 7. Specifically, a membrane 30 is placed on top of an absorbent pad 31 as shown in Figure 7. As shown in Figures 7 and 8, the pad 31 includes a hole or aperture 32 over which the membrane 30 is placed. As shown in Figure 9, the membrane 30 and pad 31 are contained within an outer housing that includes a top 33 and bottom 34. Use of the apparatus 35 is further illustrated m Figure 10.
  • Each membrane 30 includes three different antibodies, placed m discrete and separate positions, as illustrated by the kit 35f which indicates AB+ blood.
  • the kit 35a indicates a positive reading for A- blood; the kit 35b indicates a positive reading for A+ blood.
  • the kits 35c, 35d indicate positive readings for B- and B+ blood respectively.
  • kits 35e, 35f indicate positive readings for AB- and AB+ blood respectively.
  • the kits 35g, 35h provide positive readings for 0- and 0+ blood respectively.
  • the kit 35 is used as follows. Fifty microliters of blood is placed on the top of the membrane 30. The blood is then allowed to sit for sixty seconds. The membrane is then washed with lmL of the above-described buffer solution to remove the unreacted blood cells. The results as shown m Figure 10 are then interpreted. A red dot on the left hand side denotes A type antigen. A red dot on the right hand side denotes B type antigen. A red dot m the upper center portion of the membrane 30 indicates RH+ .
  • the preferred membrane is comprised of mixed esters of cellulose.
  • the preferred pore size is approximately 20 microns. However, the pore size may vary.
  • One preferred memDrane is sold under the HIFLOW-SXTM which is sold in strips that are twelve inches wide, having a thickness of 115-155 microns.
  • the top 33 and bottom 34 may be manufactured from plastic, such as PVC.
  • the backing sheet 22 may also be manufactured from plastic. Instead of utilizing a 20 micron membrane, a membrane having a smaller pore size, such as three microns may be utilized. If a 3 micron membrane is utilized, the antibodies should be applied to the top or front surface of the membrane.
  • a 20 micron membrane may be utilized alone, without being fabricated into a strip form, such as the strips 28 as shown m Figure 6 or the kits 35 as shown in Figure 10.
  • ten microliters of blood may oe mixed with twenty microliters of antibody solution with fifty microliters of buffer. This mixture may then be pipetted directly onto the membrane. A bright red spot will appear in positive samples as the agglutinated antibody red cell complex will not be able to pass through the twenty micron pore membrane. In a negative sample, the red cells pass through the membrane and no clumping is observed.
  • membrane m accordance with the present invention will be useful for other types of testing, other than blood-type testing. Specifically, the invention and methods of using the invention will be useful for the detection of viral infections, such as HIV. Further, the present invention may be utilized to detect any type of a blood condition that may be otherwise detected by agglutination or aggregation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

An improved blood testing kit and method of testing blood is provided. The improved kit may be provided in two or more forms including a strip from whereby a membrane (30) and an absorbent pad (31) are attached to a backing sheet in a juxtaposed relationship with one another. A portion of one side of the membrane (30) is treated with antibodies that will react with the antigens for A type, B type and RH+ blood. Another embodiment includes the placement of a membrane over an absorbent pad (31) within a housing. A hole or aperture (32) is disposed in the pad (31) underneath a portion of the membrane (30). Discrete portions of the membrane are treated with antibodies specific to the A type, B type and RH+ blood antigens. If the antibodies are disposed on the underside of the membrane, a membrane having a pore size of approximately 20 microns is utilized. If the antibodies are disposed on the top or upper surface of the membrane (30), a membrane having a smaller pore size of 3-8 microns is utilized.

Description

BLOOD TESTING KIT
FIELD OF THE INVENTION This invention relates generally to apparatus for testing blood including tests for blood type or viral infections, such as HIV. More specifically, this invention relates to the use of membranes in blood testing apparatuses.
BACKGROUND OF THE INVENTION
Blood testing is normally performed in a laboratory setting requiring several steps for each type of test to be performed. While the present invention is directed toward two basic type of blood tests, blood type testing and testing for viral infections, other applications will be apparent to those skilled in the art. Blood typing is performed by detecting the type of antigen that is contained within a person's blood. Specifically, a person with A type blood has the A antigen in their blood cells; people with B type blood have the B antigen in their blood cells; people with AB type blood have both the A antigen and the B antigen in their blood cells; and people with 0 type blood have neither the A nor the B antigen.
Most prior art methods of typing blood rely upon an agglutination process whereby the red cells agglutinate in the presence of a specific antigen type antibody. Specific antigen type antibodies exist for all blood types except type 0. For example, A type red blood cells will react with a specific antigen type antibody which results in a clumping or aggregation of the A type blood cells and the A type antigen antibodies. Thus, if A type blood is exposed to the specific antigen antibody for A type blood, the result is a clumping of A type red blood cells and the antibody. The visual appearance of the clumping is a positive indication that the blood is A type. Similarly, clumping will occur when B type red blood cells are exposed to B type antibodies. In the case of AB type blood, the blood sample must be exposed to both A type antibodies as well as B type antibodies. The clumping reaction for both types of antibodies is a positive indication for AB type blood. Finally, in the case of 0 type blood no clumping will occur when exposed to A type or B type antibodies. Similar agglutination methods are used for RH factor determination. A schematic diagram illustrating the agglutination method is presented in Figure 1.
Another process utilizes size exclusion chromatography. In this method, a mixture of blood and antibody is placed in a test tube on top of a layer of gel. The tube is then placed in a centrifuge. If the sample contains red cells with the specific antigen on their surface, the cells and antibody will clump together and will not be able to be centrifuged through the gel.
If the sample does not contain red cells with the specific antigen on their surface, the cells will easily be centrifuged through the gel. Therefore, red blood cells that are centrifuged through the gel is a negative reaction and a band of red cells disposed on the top of the gel after centrifuging is a positive reaction. The size exclusion chromatography method is illustrated in Figure 2. Until now, chromatography was the only method of size exclusion blood typing or blood testing. Membranes, if used at all, were merely used for an indication of a positive reaction at the surface of the membrane. However, with recent advances in membrane technology, it would be particularly useful to utilize membranes in a size exclusion blood testing method.
Specifically, the antigen or reactant could be disposed on an underside or an opposing side of a membrane. Blood then could be forced to proceed through the membrane before reacting with the antigen or other reactant. The remaining components of the blood could be thereafter absorbed or washed away leaving the blood cell-reactant aggregate disposed against the underside of the membrane. Because membranes are clear, the result could be an easy-to-read indicator such as a line or a dot. Further, separate antigens or reactants could be placed at discrete locations on the membrane to provide multiple indication in one test kit. For example, both A type and B type as well as RH positive antibodies could be placed on discrete areas of the membrane so that one test apparatus could provide positive indications for A, B, AB, O, RH positive and RH negative blood. Such a system would not require the use of a centrifuge or excessive handling by a technician.
SUMMARY OF THE INVENTION The invention is an improved apparatus for testing blood, such as testing blood type and testing for viral infections. One apparatus made in accordance with the present invention includes a backing sheet for accommodating a membrane on one surface section of the backing sheet and an absorbent pad on a second surface section of the backing sheet. The membrane and absorbent pad are in a juxtaposed relationship with one another. On the underside of the membrane, antibodies corresponding to A, B and RH positive blood cells are arranged in discrete areas of the membrane. One preferred method is to place a horizontal "stripe" of antibody corresponding to each blood type in a parallel relationship. The backing sheet, absorbent pad and membrane are then cut into strips. The purpose of the absorbent pad is to absorb liquid as it flows through the membrane. When the blood cells react with an antibody or other reagent, the aggregation is too large to pass through the membrane and a red stripe appears where the antibody or reagent was placed on the membrane.
A second and related embodiment features a membrane mounted onto the top of an absorbent pad. The absorbent pad includes a hole or aperture disposed in the middle of the pad. The membrane/ pad combination are then accommodated in a housing which includes an opening or access hole disposed above the portion of the membrane covering the hole or opening in the absorbent pad. The appropriate antibodies or reagents are previously placed in discrete areas of the membrane portion which is disposed over the hole in the pad. Blood is then applied directly to the top of the membrane and subsequently washed away with a buffer solution. Blood cells which react with the antibodies or reagents form an aggregation or bright red area after the remaining components of the blood are washed away with the buffer solution. A membrane having approximately a 20 micron pore size is preferable for use with both blood testing apparatuses described above. Red blood cells are approximately seven to eight microns in diameter. Thus, unreacted red blood cells will pass through the 20 micron membrane. However, once the red blood cells react with an antibody or other suitable reagent to produce an aggregate, the aggregate cannot pass through the 20 micron pore size. As the remaining components of the blood are washed away w ch a buffer solution, the aggregate combination is left behind :o provide a bright red indicator on the under surface of the membrane. Because the membranes are transparent, a clear visual indication is provided.
In contrast, it may be desirable to allow the blood and reagents to aggregate on the surface of the membrane. In such a situation, a membrane with a smaller pore size, such as 3-6 microns is provided so that the blood and reagents will bind to the surface of the membrane.
It is therefore an object of the present invention to provide an improved apparatus for testing blood. Yet another object of the present invention is to provide an improved blood-type testing kit.
Still another object of the present invention is to provide an improved apparatus for testing viral infections in human blood. Another object of the present invention is to provide an improved method for testing blood.
Other objects and advantages of the present invention will become apparent upon reading the following detailed description of the drawings and appended claims, and upon reference to the accompanying drawings .
BRIEF DESCRIPTION OF THE DRAWINGS The invention is illustrated more or less diagrammatically in the accompanying drawing wherein:
Figure 1 is a schematic diagram illustrating a positive reaction between an antibody and a red blood cell with the specific antigen and a negative reaction between an antibody and a red cell without the specific antigen;
Figure 2 is an illustration of the prior art method of using size exclusion chromatography in testing blood; Figure 3 is a top plan view of a plastic backing sheet used in one blood testing apparatus made in accordance with the present invention; Figure 4 is a top plan view of the plastic backing sheet shown in Figure 3 with a membrane applied to a lower surface section thereof,-
Figure 5 is an illustration of the backing sheet and membrane shown in Figure 4 further with an absorbent pad attached to the backing sheet in a juxtaposed relationship with respect to the membrane;
Figure 6 is an illustration of the embodiment shown in Figure 5, cut into strips and illustrating the reactions for A- , A+, B- , B+, AB-, AB+, O- and 0+ blood types;
Figure 7 is a side view illustrating the attachment of a membrane to an absorbent pad for a second embodiment made in accordance with the present invention;
Figure 8 is a top plan view of the absorbent pad first shown in Figure 7;
Figure 9 is a side sectional view illustrating the membrane and absorbent pad shown in Figure 7 contained within a housing; and
Figure 10 is an illustration of eight blood testing apparatus shown in Figure 9 indicating A- , A+, B-, B+ AB-, AB+, O- and 0+ blood types.
It should be understood that the drawings are not necessarily to scale and that the embodiments are sometimes illustrated by graphic symbols, phantom lines, diagrammatic representations and fragmentary views. In certain instances, details which are not necessary for an understanding of the present invention or which render other details difficult to perceive may have been omitted. It should be understood, of course, that the invention is not necessarily limited to the particular embodiments illustrated herein.
DETAILED DESCRIPTION OF THE DRAWINGS Like reference numerals will be used to refer to like or similar parts from Figure to Figure in the following description of the drawings. Turning to Figure 1, an antibody 11, a red blood cell 12 and a red blood cell 13 are shown at the left. The red blood cell 12 includes an antigen which will react positively with the antibody 11 which will result in an aggregation, shown generally at 14. The aggregation 14 is a positive reaction or a positive indication that the red blood cell 12 is of the blood type specific to the antibody 11. In contrast, the antibody 11 will not react with the red blood cell 13 because the red blood cell 13 lacks the specific antigen. The combination of the antibody 11 and the red blood cell 13 is a negative reaction or lack of clumping, indicated generally at 15. The aggregation or agglutination shown at 14 is useful in size exclusion chromatography as shown m Figure 2.
A size exclusion chromatography method is illustrated in Figure 2. A test tube 16 is filled with a gel 17. A mix type of red blood cells and a specific antibody are placed on top of the gel 17 at the area indicated generally at 18. The test tube 16 is then placed in a centrifuge (not shown) . If no reaction takes place between the antibody and the red blood cells, the red blood cells shown at 20 will centrifuge downward toward the lower end of the test tube below the gel, indicated generally at 19. The test tube shown m the middle of Figure 2 indicates a negative reaction, because the red blood cells 20 were able to pass through the gel 17 during the centrifuge process. In contrast, the red blood cells shown in the test tube 16 at the far right of Figure 2 reacted with the antibody and formed an aggregation 21 which was not able to pass through the gel 17 during the centrifuge process. As a result, the red blood cells in combination with the antibodies are shown at 21, disposed on top of the gel 17. The aggregation was unable to pass through the gel and therefore the area disposed at the bottom 19 of the test tube 16 remains clear.
The size exclusion chromatography process shown m Figure 2 is inconvenient for several reasons. Specifically, only one antibody or reagent may be used at a time. Thus, several tests are required to determine blood type which requires the use of several test tubes. Further, a centrifuge is required.
One embodiment of the present invention is illustrated in Figures 3 through 6. Figure 3 is an illustration of a backing sheet 22 which, as shown in Figure 4, accommodates a membrane 23. The dotted lines 24, 25 which pass through the membrane 23 are intended to indicate the placement of antibodies on either the top side or underside of the membrane 23. Figure 5 illustrates the placement of an absorbent pad 26 on top of the backing sheet 22 and m a juxtaposed relationship with respect to the membrane 23. As fluid passes through the membrane 23, it is absorbed into the pad 26. The apparatus 27 shown in Figure 5 can then be cut into strips 28a tnrough 28h as shown in Figure 6.
Turning now to Figure 6, the membrane 23 has been coated with three specific antibodies -- the specific antibody for A type blood, the specific antibody for B type blood and the specific antibody for RH+ blood. As illustrated to the left of the strip
28a, the A type, B type and RH+ antibodies are coated on the membrane in spaced apart parallel stripes. The use of the three different antibodies enables the test strips 28 to indicate eight different results. Specifically, the test strip 28a gives a positive indication for A- blood. The test strip 28b is a positive indication for A+ blood. The test strip 28c gives a positive indication for B- blood; the test strip 28d gives a positive indication for B+ blood. Similarly, the test strips 28e and 28f gives positive results for AB- and AB+ blood respectively.
Finally, the test strips 28g, 28h give positive results for 0- and
0+ blood respectively.
The test strips 28a through 28h as shown m Figure 6 can be used as follows: the blood samples are collected in a standard method with any type of anticoagulant to stop clotting. Approximately five microliters of blood is then added to a 12mm by 75mm test tube along with approximately 95 microliters of buffer containing 1% BSA, 50mM sodium phosphate ph 7.4, with 0.1 percent sodium azide . The strip 28 is then added to the tube with the membrane 23 on the bottom and the solution is allowed to migrate up the strip 28 to the absorbent pad 26. The results can then be observed within one to four minutes.
A second embodiment of the present invention is illustrated in Figure 7. Specifically, a membrane 30 is placed on top of an absorbent pad 31 as shown in Figure 7. As shown in Figures 7 and 8, the pad 31 includes a hole or aperture 32 over which the membrane 30 is placed. As shown in Figure 9, the membrane 30 and pad 31 are contained within an outer housing that includes a top 33 and bottom 34. Use of the apparatus 35 is further illustrated m Figure 10. Each membrane 30 includes three different antibodies, placed m discrete and separate positions, as illustrated by the kit 35f which indicates AB+ blood. The kit 35a indicates a positive reading for A- blood; the kit 35b indicates a positive reading for A+ blood. Similarly, the kits 35c, 35d indicate positive readings for B- and B+ blood respectively. The kits 35e, 35f indicate positive readings for AB- and AB+ blood respectively. Finally, the kits 35g, 35h provide positive readings for 0- and 0+ blood respectively. The kit 35 is used as follows. Fifty microliters of blood is placed on the top of the membrane 30. The blood is then allowed to sit for sixty seconds. The membrane is then washed with lmL of the above-described buffer solution to remove the unreacted blood cells. The results as shown m Figure 10 are then interpreted. A red dot on the left hand side denotes A type antigen. A red dot on the right hand side denotes B type antigen. A red dot m the upper center portion of the membrane 30 indicates RH+ .
The preferred membrane is comprised of mixed esters of cellulose. The preferred pore size is approximately 20 microns. However, the pore size may vary. One preferred memDrane is sold under the HIFLOW-SX™ which is sold in strips that are twelve inches wide, having a thickness of 115-155 microns. The top 33 and bottom 34 may be manufactured from plastic, such as PVC. The backing sheet 22 may also be manufactured from plastic. Instead of utilizing a 20 micron membrane, a membrane having a smaller pore size, such as three microns may be utilized. If a 3 micron membrane is utilized, the antibodies should be applied to the top or front surface of the membrane. The reaction or aggregation will take place on the membrane's surface as opposed to the underside of the membrane as illustrated above Finally, a 20 micron membrane may be utilized alone, without being fabricated into a strip form, such as the strips 28 as shown m Figure 6 or the kits 35 as shown in Figure 10. Specifically, ten microliters of blood may oe mixed with twenty microliters of antibody solution with fifty microliters of buffer. This mixture may then be pipetted directly onto the membrane. A bright red spot will appear in positive samples as the agglutinated antibody red cell complex will not be able to pass through the twenty micron pore membrane. In a negative sample, the red cells pass through the membrane and no clumping is observed.
The use of membrane m accordance with the present invention will be useful for other types of testing, other than blood-type testing. Specifically, the invention and methods of using the invention will be useful for the detection of viral infections, such as HIV. Further, the present invention may be utilized to detect any type of a blood condition that may be otherwise detected by agglutination or aggregation.
Althougn only a limited number of embodiments of the present invention has been illustrated and described, it will at once be apparent to those skilled in the art that variations may De made within the spirit and scope of the invention. Accordingly, it is intended that the scope of the invention be limited solely by the scope of the hereafter appended claims and not by any specific wording m the foregoing description.

Claims

WHAT IS CLAIMED IS:
1. An apparatus for testing blood, the apparatus comprising: a backing sheet including a front surface thereof, the front surface of the backing sheet including a first section and a section; a membrane sheet being attached to the first section of the backing sheet, a first limited portion of the membrane sheet being coated with an antibody; an absorbent pad being attached to the section of the backing sheet, the membrane sheet and absorbent pad being in juxtaposed relationship with one another.
2. The apparatus of claim 1, wherein the membrane has a pore size ranging from about 3 microns to about 25 microns.
3. The apparatus of claim 2, wherein the pore size about 20 microns.
4. The apparatus of claim 2, wherein the pore size about 3 microns.
5. The apparatus of claim 1, wherein the antibody is selected from the group consisting of antibody for A antigen, antibody for B antigen and antibody for RH positive antigen.
6. The apparatus of claim 5 , wherein the membrane sheet includes a second limited portion that does not overlap said first limited portion, the second limited portion being coated with an antibody that is different than the antibody that the first limited portion is covered with.
7. The apparatus of claim 6, wherein the membrane sheet includes third limited portion that does not overlap said first and second limited portions, the second limited portion being coated with an antibody that is different than the antibodies that the first and second limited portions are covered with.
8. An apparatus for testing blood, the apparatus comprising: a backing sheet including a front surface thereof, the front surface of the backing sheet including a first section and a section; a membrane sheet being attached to the first section of the backing sheet, the membrane including a pore size of approximately 20 microns, a first limited portion of the membrane sheet being coated with an antibody selected from the group consisting of antibody for A antigen, antibody for B antigen, and antibody for RH positive antigen, a second limited portion that does not overlap said first limited portion, the second limited portion being coated with an antibody that is different than the antibody that the first limited portion is covered with, a third limited portion that does not overlap said first and second limited portions, the second limited portion being coated with an antibody that is different than the antibodies that the first and second limited portions are covered with; an absorbent pad being attached to the section of the backing sheet, the membrane sheet and absorbent pad being m juxtaposed relationship with one another.
9. An apparatus for testing blood, the apparatus comprising: a bottom receptacle including an upper opening defined by an upper rim for accommodating a membrane sheet and an absorbent pad; the membrane sheet overlying the absorbent pad, a first limited portion of the membrane sheet being coated with an antibody selected from the group consisting of antibody for A antigen, antibody for B antigen and antibody for RH positive antigen; the absorbent pad including an opening, the first limited portion of the membrane sheet being suspended over an area defined by the opening of the absorbent pad.
10. The apparatus of claim 9, wherein the membrane has a pore size ranging from about 3 microns to about 25 microns.
11. The apparatus of claim 10, wherein the pore size about 20 microns.
12. The apparatus of claim 10, wherein the pore size about 3 microns.
13. The apparatus of claim 9, wherein the membrane sheet includes a second limited portion disposed within the opening of the absorbent pad, the second limited portion does not overlap said first limited portion, the second limited portion being coated with an antibody that is different than the antibody that the first limited portion is covered with.
14. The apparatus of claim 12, wherein the membrane sheet includes third limited portion disposed within the opening of the absorbent pad, the tnird limited portion does not overlap said first and second limited portions, the third limited portion being coated with an anticody that is different than the antibodies that the first and second limited portions are covered with.
15. A method for testing blood comprising the following steps : collecting a blood sample; adding an anticoagulant to the blood sample; adding BSA to the blood sample; placing a blood testing apparatus in the blood sample, the blood testing apparatus including a backing sheet including a front surface thereof, the front surface of the backing sheet including a first section and a section, a membrane sheet being attached to the first section of the backing sheet, a first limited portion of the membrane sheet being coated with an antibody selected from the group consisting of antibody for A antigen, antibody for B antigen and antibody for RH positive antigen, an absorbent pad being attached to the section of the backing sheet, the membrane sheet and absorbent pad being m juxtaposed relationship with one another; waiting for blood to adhere to the first limited portion of the membrane.
16. A method for testing blood comprising the following steps : collecting a blood sample; adding an anticoagulant to the blood sample; adding BSA to the blood sample; placing the blood sample into a blood testing apparatus, the blood testing apparatus including a .bottom receptacle including an upper opening defined by an upper rim for accommodating a membrane sheet and an absorbent pad, the membrane sheet overlying the absorbent pad, a first limited portion of the membrane sheet being coated with an antibody selected from the group consisting of antibody for A antigen, antibody for B antigen and antibody for RH positive antigen, the absorbent pad including an opening, the first limited portion of the membrane sheet being disposed within the opening of the absorbent pad; waiting for blood to adhere to the first limited portion of the membrane.
17. A method for testing blood comprising the following steps : collecting a blood sample; adding an anticoagulant to the blood sample; adding BSA to the blood sample; adding an antibody to the blood sample; placing a portion of the blood sample onto a membrane; waiting for blood and antibody to adhere to the membrane or pass through the membrane.
PCT/US1997/002889 1996-03-01 1997-02-27 Blood testing kit WO1997032213A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21912/97A AU2191297A (en) 1996-03-01 1997-02-27 Blood testing kit

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60970596A 1996-03-01 1996-03-01
US08/609,705 1996-03-01

Publications (1)

Publication Number Publication Date
WO1997032213A1 true WO1997032213A1 (en) 1997-09-04

Family

ID=24441977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/002889 WO1997032213A1 (en) 1996-03-01 1997-02-27 Blood testing kit

Country Status (2)

Country Link
AU (1) AU2191297A (en)
WO (1) WO1997032213A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020862A1 (en) * 1998-10-02 2000-04-13 Abp Diagnostics Ltd. Process and apparatus for the in vitro detection of multiple analytes
WO2005003787A1 (en) * 2003-07-08 2005-01-13 Inverness Medical Switzerland Gmbh Particle agglutination detection method and device
WO2005005991A1 (en) * 2003-07-09 2005-01-20 Medion Diagnostics Gmbh Device and method for simultaneously identifying blood group antigens
WO2006051548A2 (en) * 2004-11-15 2006-05-18 Inverness Medical Switzerland Gmbh Blood type method system and device
WO2007029250A1 (en) * 2005-09-06 2007-03-15 Inverness Medical Switzerland Gmbh Method and apparatus for patterning a bibulous substrate
FR2931244A1 (en) * 2008-05-13 2009-11-20 Biosynex Sarl DEVICE FOR DETECTING AT LEAST ONE ELEMENT CONTAINED IN A BLOOD SOLUTION
EP1644735B1 (en) * 2003-07-09 2011-09-21 Medion Diagnostics AG Device for lateral flow tests
CN102288746A (en) * 2011-07-12 2011-12-21 英科新创(厦门)科技有限公司 Blood screening joint detection card
WO2012159275A1 (en) * 2011-05-26 2012-11-29 Siemens Aktiengesellschaft Blood typing system
CN103502819A (en) * 2011-04-21 2014-01-08 西门子公司 Blood typing devices and methods for testing blood type
WO2021175239A1 (en) * 2020-03-04 2021-09-10 重庆大学 Automatic multi-blood-group system test card and test method

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379847A (en) * 1979-09-19 1983-04-12 American Hospital Supply Corporation Suspending medium for immunologic reactions
US4459361A (en) * 1982-06-04 1984-07-10 Angenics, Inc. Ligand assay with one or two particulate reagents and filter
US4552839A (en) * 1983-08-01 1985-11-12 Syntex (U.S.A.) Inc. Determination of analytes in particle-containing medium
WO1988008534A1 (en) * 1987-04-27 1988-11-03 Unilever Plc Immunoassays and devices therefor
US4851210A (en) * 1986-05-22 1989-07-25 Genelabs Incorporated Blood typing device
US4943522A (en) * 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5213963A (en) * 1988-10-12 1993-05-25 Biotest Aktiengesellschaft Procedure for finding and identifying red cell antibodies by means of the solid phase method

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379847A (en) * 1979-09-19 1983-04-12 American Hospital Supply Corporation Suspending medium for immunologic reactions
US4459361A (en) * 1982-06-04 1984-07-10 Angenics, Inc. Ligand assay with one or two particulate reagents and filter
US4552839A (en) * 1983-08-01 1985-11-12 Syntex (U.S.A.) Inc. Determination of analytes in particle-containing medium
US4851210A (en) * 1986-05-22 1989-07-25 Genelabs Incorporated Blood typing device
WO1988008534A1 (en) * 1987-04-27 1988-11-03 Unilever Plc Immunoassays and devices therefor
US4943522A (en) * 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5213963A (en) * 1988-10-12 1993-05-25 Biotest Aktiengesellschaft Procedure for finding and identifying red cell antibodies by means of the solid phase method

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020862A1 (en) * 1998-10-02 2000-04-13 Abp Diagnostics Ltd. Process and apparatus for the in vitro detection of multiple analytes
WO2005003787A1 (en) * 2003-07-08 2005-01-13 Inverness Medical Switzerland Gmbh Particle agglutination detection method and device
KR101214620B1 (en) 2003-07-09 2012-12-21 메디온 디아그노스틱스 아게 Device and method for simultaneously identifying blood group antigens
WO2005005991A1 (en) * 2003-07-09 2005-01-20 Medion Diagnostics Gmbh Device and method for simultaneously identifying blood group antigens
EP1644735B1 (en) * 2003-07-09 2011-09-21 Medion Diagnostics AG Device for lateral flow tests
US8053226B2 (en) 2003-07-09 2011-11-08 Medion Diagnostics Ag Device and method for simultaneously identifying blood group antigens
WO2006051548A2 (en) * 2004-11-15 2006-05-18 Inverness Medical Switzerland Gmbh Blood type method system and device
WO2006051548A3 (en) * 2004-11-15 2007-05-24 Inverness Medical Switzerland Blood type method system and device
WO2007029250A1 (en) * 2005-09-06 2007-03-15 Inverness Medical Switzerland Gmbh Method and apparatus for patterning a bibulous substrate
FR2931244A1 (en) * 2008-05-13 2009-11-20 Biosynex Sarl DEVICE FOR DETECTING AT LEAST ONE ELEMENT CONTAINED IN A BLOOD SOLUTION
CN103502819A (en) * 2011-04-21 2014-01-08 西门子公司 Blood typing devices and methods for testing blood type
WO2012159275A1 (en) * 2011-05-26 2012-11-29 Siemens Aktiengesellschaft Blood typing system
CN103765221A (en) * 2011-05-26 2014-04-30 西门子公司 Blood typing system
CN102288746A (en) * 2011-07-12 2011-12-21 英科新创(厦门)科技有限公司 Blood screening joint detection card
WO2021175239A1 (en) * 2020-03-04 2021-09-10 重庆大学 Automatic multi-blood-group system test card and test method

Also Published As

Publication number Publication date
AU2191297A (en) 1997-09-16

Similar Documents

Publication Publication Date Title
EP0556202B1 (en) Improved ligand assay
US3552925A (en) Whole blood separation method and test using same
US4952520A (en) Immunoassay making use of latex agglutination
EP0269876B1 (en) Sample focuser for solid-phase analytical device
US4111754A (en) Immunological testing devices and methods
US5096809A (en) Whole blood assays using porous membrane support devices
JP5181058B2 (en) Method and kit for rapidly determining human ABO / RH / MN blood type
US5147780A (en) Multiwell stat test
US4639419A (en) Immunological color change test involving two differently colored reagent spots
US4965187A (en) Method and apparatus for assaying whole blood
CA2048530A1 (en) Membranes and membrane overlays for exclusion of erythrocytes for solid state assays
US5753497A (en) Diagnostic assay providing blood separation
US20060193746A1 (en) Multiple analyte assay devices
WO1987007304A1 (en) Cell detection system and method
USRE30562E (en) Immunological testing devices
US4939096A (en) Method and apparatus for assaying whole blood
WO1997032213A1 (en) Blood testing kit
EP1230550B1 (en) Flow matrix assay device with movable separating member
EP0239174B1 (en) Biological diagnostic device
US8546084B2 (en) Device and method for identifying and determining blood groups
EP0283613A2 (en) Dry test strip suitable for oxygen demanding detection system
WO1996015453A1 (en) Method and device for determination of proteins employing antigen/antibody reactions
WO2001024931A1 (en) Capillary device for separating undesired components from a liquid sample and related method
EP0324603A2 (en) Improved solid phase enzyme immunoassay test apparatus and process for detection antibodies
EP0439917B1 (en) Apparatus for detection and semi-quantitative measurement of analytes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97531060

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase